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Abstract 
 
The methanol extract of Gladiolus psittascinus bulb was evaluated for its antidiabetic 
activities in alloxan-induced diabetic rats. Blood glucose levels of the glucose loaded and alloxan-
induced diabetic rats were estimated over 180 minutes using the O-toluidine and glucose-oxidase 
methods.  The methanol extract at 1g/kg dose exhibited 16.2% decrease in blood glucose level in the 
glucose loaded rats and a peak effect of 78.9% in the alloxan-induced diabetic rats. The extract 
exhibited significant blood glucose lowering effects in the oral glucose tolerance test and type 2 
diabetic rats.  This study shows a possible beneficial effect of Gladiolus psittascinus in the 
management of non-insulin dependent diabetes (NIDDM). 
 
Keywords: Gladiolus psittascinus, hypoglycaemic activity, diabetes mellitus. 
 
 
Introduction 
 
Diabetes mellitus is a major public health problem. According to WHO reports, more than 176 million 
patients  suffer worldwide and it is estimated that in 2025, there will be about 300 million patients 
living with this condition. The increase is expected to be 42% in developed countries and 70% in 
developing countries (WHO, 2006; King et al., 1998). Although different types of hypoglycaemic 
agents such as thiazolidinediones, insulin, biguanides and sulphunylurea are available; there is growing 
interest in herbal remedies due to the side effects associated with these therapeutic agents (Prout,1974; 
Holman and Turner, 1991; Kameswara Rao et al., 1997) beside their limitations in managing the 
disease effectively (Maggs et al., 1998; Misbin et al., 1997). 
 Gladilous psittascinus Hook (Iridaceae) an herbaceous plant is commonly known as Maid of 
the mist’ or ‘dragon’s head lily’ and ‘Baaka’ (Yoruba, South west Nigeria).  It occurs virtually 
throughout the grasslands, savannas and woodlands of sub-Saharan Africa. Ethnomedicinally, it is used 
as remedy for cold, dysentery, asthma, gonorrhoea and intestinal parasites (Adjanohoun et al., 1991. 
In our previous ethnobotanical study, Gladiolus psittascinus was used by traditional healers in 
South West Nigeria as an important recipe for treating diabetes mellitus (Fred-Jaiyesimi, 2007). From 
this point of view, this study aimed at investigating the antidiabetic effect of Gladiolus psittascinus 
using oral glucose tolerance test and alloxan-induced type 2 diabetic rats. 
 
Materials and Methods 
Plant materials 
 
Gladiolus psittascinus bulb (voucher No. FHS 007B) was bought from Falawo Market, 
Sagamu. Nigeria. Botanical identification was performed at the Department of Pharmacognosy, 
OlabisiOnabanjo University, Sagamu. The bulbs were sliced, air dried and ground into powder. 
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Extraction of methanolic plant material 
 
Two hundred grams of the bulb powder were macerated in 80% methanol for four days.  The 
extract was filtered, concentrated to dryness under reduced pressure at a temperature of 40oC. The 
extract yield was 2.65% w/w (based on the dried starting material). 
 
Animals 
 
Healthy Wister albino rats with average weight of 140g were used for this study. The animals 
were kept and maintained under standard conditions ( 12h light and dark cycle and room temperature at 
25OC)  and were fed with standard pellet diet (Ladokun Feeds, Ibadan) and water ad libitum. 
Experimetal designs for the oral glucose tolerance test and  NIDDM assay are indicated 
below. The experimental protocols were conducted in accordance with internationally accepted 
standard guidelines for care and use of laboratory animals. 
 
 
Experimental design 
 
Animals were divided into four groups (n = 5) and treated orally as follow: group 1, received 
the plant extract (1g/kg b.w); group 2, received glucose solution (2 g/kg b.w); group 3, received 
glibenclamide (5mg/kg b.w) and group 4, received water (control group). 
 
Oral glucose tolerance test 
 
Oral glucose tolerance test was performed in overnight fasted (18 hrs) normal rats..Just after 
glucose administration, the test sample and standard reference drugs were administered. Blood 
waswithdrawn from the tail of each animal at 0, 30, 60, 90, 120 and 180 mins. The fasting blood 
glucose levels were estimated by the O-toluidine method (Dubowski, 1962; Frings et al, 1970). 
 
 
Induction of non-insulin dependent diabetes mellitus (NIDDM). 
 
Non-insulin dependent diabetes mellitus was induced in overnight fasted animals by a single 
intraperitoneal injection of 60 mg/kg alloxan monohydrate (Sigma Aldrich, UK) solution. 
Hyperglycaemia was confirmed by the elevated glucose levels in blood and was determined 72 hr after 
injection. 
 
Hypoglycaemic activity evaluation 
 
The diabetic animals were divided into four groups. Group 1 diabetic rats received G. 
psittascinus extract, Group 2 were administered Glibenclamide (5mg/kg), Group 3 diabetic untreated 
rats received distilled water (2 ml/kg bw) while Group 4 normal non-diabetic rats also received distilled 
water (2ml/kg bw). Blood samples were collected via the tail and blood glucose levels was measured at 
0, 30, 60, 90, 120 and 180 min with a glucometer (Lifescan, Johnson and Johnson Inc. California). 
 
Statistical analysis 
 
Data were expressed as mean ± SEM. The significance of the differences between the means 
of the test and control animals was established by the student’s t-test. 
 
 
Result and Discussion 
 
Oral administration of the methanol extract of G. psittascinus bulbs at 1g/kg body weight 
produced significant (P<0.05) hypoglycaemic effects in the oral glucose tolerance test at 90, 120 and 
180 mins (Table 1). The most pronounced effect was observed at 120 min with 16.2% decrease in 
blood glucose level. The animals treated with glibenclamide (5mg/kg) showed a significant reduction 
in blood glucose level after 30 min when compared with the blood glucose level of the untreated 
glucose loaded rats. In the alloxan–induced diabetic rats, the methanol extract exhibited 78.9% glucose 
loweringeffect within the first 60 min of administration.
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Table 1:  Effect of methanol bulb extract of Gladiolus psittascinus on oral glucose tolerance test. Values are Mean ± SEM; p < 0.05; n = 5; Figures in parenthesis 
= % decrease, * Significant difference in glucose level when compared with control glucose untreated values (P<0.05). 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2:  Effect of methanol bulb extract of Gladiolus psittacinus on blood glucose level of alloxan- induced diabetic rats. 
Values are Mean ± SEM; P<0.05; n = 5; Figures in parenthesis = % decrease,* Significant difference in glucose level when compared with   control diabetic untreated 
values (P<0.05). 
Gladiolus psittascinus             MEAN BLOOD GLUCOSE LEVEL (mg/dl). 
Time (minutes)                   0                          30                   60                    90                        120                         180 
Group 1 (methanol 
Extract) 1g/kg.                   94.8 ±                 158.2 ±            151.0  ±          130.2 ±               133.8 ±                     131.2 ± 
                                           1.323                  0.558                0.294              0.321                  0.963                         2.094 
(percentage of reduction)                                                      (3.4 %)            (15.5%*)           (16.2%*)                   (14.2%*) 
Group 2  
Glibenclamide                    81.5 ±                132.5 ±             98.9 ±              92.4 ±                99.8 ±                        88.1 ±    
(5mg/kg).                            0.006                 0.014                0.006               0.008                  0.003                         0.005   
 (percentage of reduction)                            (12.3)              ( 36.7%*)         (40%*)                (37.5%*)                   (42.4%*) 
Group 3 
Glucose untreated              89.1 ±                151.3 ±            156.3 ±           154.0 ±              159.7 ±                      152.9 ± 
Control.                              0.057                 0.031                0.074               0.037                 0.093                        0.375        
Group 4 
Normal                               85.3 ±                80.1 ±                82.1 ±             84.8 ±                85.0 ±                        85.3 ± 
(non-diabetic).                   0.085                  0 .437                0.050               0.150                 0.044                           0.075   
Gladiolus psittacinus extract. Blood glucose level (mg/dl). 
Time (minutes). 0 30 60 90 120 180 
Group 1 extract  (1g/kg) 145.0 ±6.816 123.0 ± 2.225 
(61.3  %)* 
124.6 ± 1.472 
( 78.9 %)* 
119.0 ± 1.608 
( 69.6 %)* 
119.3 ±4.816 
(70.2  %)* 
116.3 ±0.117 
(75.6  %)* 
Group 2 Glibenclamide (5mg/kg) 220.1 ±0.254 187.6 ± 0.112 
(61.7%)* 
175.4 ±0.005 
(60.4%) 
131.5 ±0.071 
(69.5%)* 
126.9 ±0.319 
(69.7%)* 
120.5±0.215 
(70.2%)* 
Group 3 Diabetic untreated (Control). 300.0± 3.360 489.3± 0.992 443.3 ± 1.216 431.0± 0.627 418.2 ± 0.008 404.7± 0.581 
 
Group  4 Normal (non-diabetic) 88.0 ±  0.246 91.3± 0.275 92.2 ±0.134 87.0 ± 0.103 89.1 ± 0.531 90.1± 0.240 
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The standard reference drug (glibenclamide) at a dose of 5mg/kg exhibited 61.7% decrease and a peak effect of 
70.2% at 180 min. The effect of the methanol extract and glibenclamide in the diabetic rats when compared with 
the control (untreated diabetic rats) showed similarity in the activity of the two treatments. The data of the 
present study shows that G. psittascinus may have beneficial effect in non-insulin dependent diabetes mellitus. 
Methanol extracts are known to contain chemical compounds each of which is capable of producing definite 
biological activities (Ojewole, 2003), the methanol extract of G. psittascinus exhibited a pronounced glucose 
lowering effect in the alloxan-induced diabetic rats.  Although the exact mechanism of action of the extract is 
unknown, the effect exhibited suggests a possible stimulation of insulin release from the residual β-cells and 
glucagon inhibition.  In addition, the extract might have an insulin-like effect acting by improving the glucose 
uptake and metabolism or by inhibiting gluconeogenesis thereby exerting the hypoglycaemic effect. Further 
studies needs however  to be carried out to identify the exact mechanism of action of G. psittascinus and  the 
compound(s) responsible for the hypoglycaemic activity. 
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